SANA Long Call Strategy
SANA (Sana Biotechnology, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
SANA (Sana Biotechnology, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $890.5M, a beta of 2.18 versus the broader market, a 52-week range of 1.6-6.55, average daily share volume of 3.0M, a public-listing history dating back to 2021, approximately 194 full-time employees. These structural characteristics shape how SANA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.18 indicates SANA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on SANA?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current SANA snapshot
As of May 15, 2026, spot at $3.08, ATM IV 80.20%, IV rank 20.06%, expected move 22.99%. The long call on SANA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on SANA specifically: SANA IV at 80.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a SANA long call, with a market-implied 1-standard-deviation move of approximately 22.99% (roughly $0.71 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SANA expiries trade a higher absolute premium for lower per-day decay. Position sizing on SANA should anchor to the underlying notional of $3.08 per share and to the trader's directional view on SANA stock.
SANA long call setup
The SANA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SANA near $3.08, the first option leg uses a $3.08 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SANA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SANA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.08 | N/A |
SANA long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
SANA long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on SANA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on SANA
Long calls on SANA express a bullish thesis with defined risk; traders use them ahead of SANA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
SANA thesis for this long call
The market-implied 1-standard-deviation range for SANA extends from approximately $2.37 on the downside to $3.79 on the upside. A SANA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current SANA IV rank near 20.06% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SANA at 80.20%. As a Healthcare name, SANA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SANA-specific events.
SANA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SANA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SANA alongside the broader basket even when SANA-specific fundamentals are unchanged. Long-premium structures like a long call on SANA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current SANA chain quotes before placing a trade.
Frequently asked questions
- What is a long call on SANA?
- A long call on SANA is the long call strategy applied to SANA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With SANA stock trading near $3.08, the strikes shown on this page are snapped to the nearest listed SANA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SANA long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the SANA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 80.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SANA long call?
- The breakeven for the SANA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SANA market-implied 1-standard-deviation expected move is approximately 22.99%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on SANA?
- Long calls on SANA express a bullish thesis with defined risk; traders use them ahead of SANA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current SANA implied volatility affect this long call?
- SANA ATM IV is at 80.20% with IV rank near 20.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.